Despite market challenges due to the COVID-19 pandemic, 2020 was a game-changing year for enabling technology for orthopedic surgery with robotics hitting an inflection point in acceptance, with record placements in Q420, and enabling technology across the entire continuum of care making significant inroads.
In Q420, MAKO* robot demand drove much of the 12.3% growth in Stryker’s* US Ortho Other segment. In 2020, MAKO’s installed base grew by 33%, and in Q420 hit a milestone of > 100 system installations at major teaching institutions, ASCs and in competitive accounts in the quarter. In fact, according to the Company, MAKO is now available in ~50% of fellowship programs at teaching institutions in US, as well as some in Europe, which will help the transition to standard of care. Stryker noted that new market entrants (Zimmer Biomet’s* ROSA*, Smith & Nephew’s* CORI* and DePuy Synthes’* VELYS*) have not slowed MAKO momentum.
Among the many topics covered in the comprehensive Q420/FY20 CAS Ortho Market Recap* are: